Improving Latent Tuberculosis (TB) Diagnosis in Thai Children (TB Px)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00947609|
Recruitment Status : Completed
First Posted : July 28, 2009
Last Update Posted : June 6, 2012
|Condition or disease|
|Latent Tuberculosis HIV Infections|
- To compare the utility of IGRAs, T-Spot®.TB and QuantiFERON®-TB Gold In-Tube, and TST for screening of latent TB in HIV-infected children
- To compare these different screening modalities in HIV-infected children to HIV uninfected children
- To assess the influence of age, nutritional and immune status, prior BCG and TST status on children's response to IGRAs
- To assess the prognostic value of IGRAs vs. TST in predicting development of active TB in children over 9 months
What is the sensitivity and specificity of IGRAs and TST in screening for latent TB in HIV-infected and HIV uninfected children in Thailand?
How do age, nutritional and immune status, prior BCG and PPD status influence children's response to IGRAs? What is the prognostic value of IGRAs vs. TST in predicting development of active TB in children over 9 months?
This is a prospective cohort study conducted at two sites in Bangkok, Thailand: HIV Netherlands Australia Thailand (HIV-NAT) Clinic/Chulalongkorn Hospital and Queen Sirikit National Institute of Child Health.
|Study Type :||Observational|
|Actual Enrollment :||158 participants|
|Official Title:||Improving the Diagnosis and Management of Latent Tuberculosis in Thai Children|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||December 2011|
|Actual Study Completion Date :||December 2011|
HIV-infected and HIV-uninfected children
HIV-infected and HIV uninfected children with recent exposure to adults with active tuberculosis will be referred to the two study sites (HIV-NAT/Chulalongkorn and Queen Sirikit) for eligibility screening and enrollment in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00947609
|HIV Netherlands Australia Thailand (HIV-NAT) Research Organization|
|Queen Sirikit National Institute of Child Health|
|Principal Investigator:||Jintanat Ananworanich, MD, PhD||South East Asia Research Collaboration with Hawaii, HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand|
|Principal Investigator:||Piyarat Suntarattiwong, MD||Queen Sirikit National Institute of Child Health, Bangkok, Thailand|
|Principal Investigator:||Simon Tsiouris, MD, MPH||Columbia University|